Overview

Vascular Endothelial Dysfunction in Sleep Apnea

Status:
Not yet recruiting

Trial end date:
2026-08-01

Target enrollment:
0

Participant gender:
All

Summary

This double-blind placebo-controlled parallel group randomized study design will be used to test whether 4 weeks of atorvastatin 10 mg daily reduces levels of inflammatory markers in OSA patients treated with CPAP (standard of care). The purpose of this study is to investigate: 1) whether statins reduce endothelial inflammation and pro-thrombotic conditions in OSA, including in patients adherent to CPAP (Aim 1); and 2) whether statins reduce endothelial inflammation and pro-thrombotic conditions by improving endothelial cholesterol metabolism and trafficking in OSA (Aim 2).

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Columbia University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Atorvastatin

Criteria

Inclusion Criteria:

- Aged ≥18 years

- Newly diagnosed with obstructive sleep apnea (OSA) who were never treated with CPAP.
OSA is defined as apnea-hypopnea index (AHI) ≥5 events/hour of sleep.

Exclusion Criteria:

- A history of coronary artery disease, heart failure, stroke, diabetes, malignancy,
chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking
within the past 5 years

- Regular use of any medications